nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—ABCB1—Mitomycin—urinary bladder cancer	0.195	0.322	CbGbCtD
Etravirine—CYP3A4—Thiotepa—urinary bladder cancer	0.0885	0.146	CbGbCtD
Etravirine—ABCB1—Gemcitabine—urinary bladder cancer	0.0561	0.0926	CbGbCtD
Etravirine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0494	0.0816	CbGbCtD
Etravirine—CYP2C9—Cisplatin—urinary bladder cancer	0.042	0.0693	CbGbCtD
Etravirine—ABCB1—Cisplatin—urinary bladder cancer	0.0407	0.0673	CbGbCtD
Etravirine—ABCB1—Etoposide—urinary bladder cancer	0.04	0.0661	CbGbCtD
Etravirine—ABCB1—Doxorubicin—urinary bladder cancer	0.0273	0.0451	CbGbCtD
Etravirine—ABCB1—Methotrexate—urinary bladder cancer	0.0265	0.0437	CbGbCtD
Etravirine—CYP3A4—Etoposide—urinary bladder cancer	0.024	0.0396	CbGbCtD
Etravirine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0164	0.027	CbGbCtD
Etravirine—CYP2C19—urine—urinary bladder cancer	0.00471	0.2	CbGeAlD
Etravirine—CYP2C9—urine—urinary bladder cancer	0.00365	0.155	CbGeAlD
Etravirine—ABCB4—vagina—urinary bladder cancer	0.00353	0.151	CbGeAlD
Etravirine—CYP3A4—urine—urinary bladder cancer	0.00278	0.119	CbGeAlD
Etravirine—ABCB4—lymph node—urinary bladder cancer	0.00229	0.0974	CbGeAlD
Etravirine—CYP2C19—vagina—urinary bladder cancer	0.000834	0.0355	CbGeAlD
Etravirine—CYP2C9—female reproductive system—urinary bladder cancer	0.000715	0.0305	CbGeAlD
Etravirine—ABCB1—prostate gland—urinary bladder cancer	0.000707	0.0301	CbGeAlD
Etravirine—CYP3A4—renal system—urinary bladder cancer	0.000681	0.029	CbGeAlD
Etravirine—ABCB1—seminal vesicle—urinary bladder cancer	0.000598	0.0255	CbGeAlD
Etravirine—CYP3A4—female reproductive system—urinary bladder cancer	0.000545	0.0232	CbGeAlD
Etravirine—ABCB1—epithelium—urinary bladder cancer	0.000519	0.0221	CbGeAlD
Etravirine—ABCB1—renal system—urinary bladder cancer	0.000482	0.0205	CbGeAlD
Etravirine—CYP2C19—Biological oxidations—GSTZ1—urinary bladder cancer	0.00048	0.00506	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000474	0.00499	CbGpPWpGaD
Etravirine—ABCB1—urethra—urinary bladder cancer	0.000473	0.0202	CbGeAlD
Etravirine—ABCB4—Metabolism—SLC19A1—urinary bladder cancer	0.000459	0.00484	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—GSTO2—urinary bladder cancer	0.000455	0.0048	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—NAT1—urinary bladder cancer	0.000455	0.0048	CbGpPWpGaD
Etravirine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000451	0.00475	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000449	0.00473	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PRSS3—urinary bladder cancer	0.000448	0.00471	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000438	0.00461	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000432	0.00455	CbGpPWpGaD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000425	0.00447	CbGpPWpGaD
Etravirine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000423	0.00445	CbGpPWpGaD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000423	0.00445	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—UGT2B7—urinary bladder cancer	0.000417	0.00439	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000415	0.00437	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000415	0.00437	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000411	0.00433	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00041	0.00431	CbGpPWpGaD
Etravirine—ABCB1—female reproductive system—urinary bladder cancer	0.000386	0.0164	CbGeAlD
Etravirine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000384	0.00139	CcSEcCtD
Etravirine—Pancreatitis—Epirubicin—urinary bladder cancer	0.000384	0.00139	CcSEcCtD
Etravirine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000383	0.00139	CcSEcCtD
Etravirine—Angina pectoris—Epirubicin—urinary bladder cancer	0.000381	0.00138	CcSEcCtD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000381	0.00401	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00038	0.004	CbGpPWpGaD
Etravirine—Breast disorder—Doxorubicin—urinary bladder cancer	0.000379	0.00137	CcSEcCtD
Etravirine—Anorexia—Etoposide—urinary bladder cancer	0.000379	0.00137	CcSEcCtD
Etravirine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000378	0.00137	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000377	0.00137	CcSEcCtD
Etravirine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000377	0.00137	CcSEcCtD
Etravirine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000377	0.00137	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.000375	0.00395	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000375	0.00394	CbGpPWpGaD
Etravirine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000374	0.00136	CcSEcCtD
Etravirine—Gastritis—Doxorubicin—urinary bladder cancer	0.000371	0.00134	CcSEcCtD
Etravirine—Pain—Cisplatin—urinary bladder cancer	0.000371	0.00134	CcSEcCtD
Etravirine—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00037	0.00389	CbGpPWpGaD
Etravirine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00037	0.00134	CcSEcCtD
Etravirine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000368	0.00133	CcSEcCtD
Etravirine—Renal failure—Methotrexate—urinary bladder cancer	0.000367	0.00133	CcSEcCtD
Etravirine—Dizziness—Thiotepa—urinary bladder cancer	0.000366	0.00133	CcSEcCtD
Etravirine—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000365	0.00132	CcSEcCtD
Etravirine—Stomatitis—Methotrexate—urinary bladder cancer	0.000364	0.00132	CcSEcCtD
Etravirine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000363	0.00131	CcSEcCtD
Etravirine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000362	0.00131	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000359	0.00378	CbGpPWpGaD
Etravirine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000359	0.0013	CcSEcCtD
Etravirine—ABCB4—Metabolism—TYMP—urinary bladder cancer	0.000358	0.00377	CbGpPWpGaD
Etravirine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000357	0.0013	CcSEcCtD
Etravirine—Paraesthesia—Etoposide—urinary bladder cancer	0.000357	0.00129	CcSEcCtD
Etravirine—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000355	0.00129	CcSEcCtD
Etravirine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000353	0.00128	CcSEcCtD
Etravirine—Somnolence—Etoposide—urinary bladder cancer	0.000353	0.00128	CcSEcCtD
Etravirine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000353	0.00128	CcSEcCtD
Etravirine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000353	0.00128	CcSEcCtD
Etravirine—Vomiting—Thiotepa—urinary bladder cancer	0.000352	0.00127	CcSEcCtD
Etravirine—ABCB1—vagina—urinary bladder cancer	0.000349	0.0149	CbGeAlD
Etravirine—Rash—Thiotepa—urinary bladder cancer	0.000349	0.00126	CcSEcCtD
Etravirine—Dermatitis—Thiotepa—urinary bladder cancer	0.000348	0.00126	CcSEcCtD
Etravirine—Headache—Thiotepa—urinary bladder cancer	0.000346	0.00126	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000346	0.00125	CcSEcCtD
Etravirine—Decreased appetite—Etoposide—urinary bladder cancer	0.000345	0.00125	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000344	0.00362	CbGpPWpGaD
Etravirine—Renal failure—Epirubicin—urinary bladder cancer	0.000343	0.00124	CcSEcCtD
Etravirine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000343	0.00124	CcSEcCtD
Etravirine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000343	0.00124	CcSEcCtD
Etravirine—Fatigue—Etoposide—urinary bladder cancer	0.000342	0.00124	CcSEcCtD
Etravirine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000342	0.00124	CcSEcCtD
Etravirine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000342	0.0036	CbGpPWpGaD
Etravirine—Stomatitis—Epirubicin—urinary bladder cancer	0.00034	0.00123	CcSEcCtD
Etravirine—Pain—Etoposide—urinary bladder cancer	0.00034	0.00123	CcSEcCtD
Etravirine—Constipation—Etoposide—urinary bladder cancer	0.00034	0.00123	CcSEcCtD
Etravirine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000339	0.00123	CcSEcCtD
Etravirine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000337	0.00355	CbGpPWpGaD
Etravirine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000337	0.00122	CcSEcCtD
Etravirine—Hepatitis—Methotrexate—urinary bladder cancer	0.000335	0.00121	CcSEcCtD
Etravirine—Asthenia—Gemcitabine—urinary bladder cancer	0.000334	0.00121	CcSEcCtD
Etravirine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000331	0.0012	CcSEcCtD
Etravirine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00033	0.0012	CcSEcCtD
Etravirine—Nausea—Thiotepa—urinary bladder cancer	0.000328	0.00119	CcSEcCtD
Etravirine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000328	0.00119	CcSEcCtD
Etravirine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000327	0.00119	CcSEcCtD
Etravirine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000327	0.00118	CcSEcCtD
Etravirine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000325	0.00118	CcSEcCtD
Etravirine—ABCB4—Metabolism—NAT2—urinary bladder cancer	0.000324	0.00341	CbGpPWpGaD
Etravirine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00032	0.00116	CcSEcCtD
Etravirine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000319	0.00116	CcSEcCtD
Etravirine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000318	0.00115	CcSEcCtD
Etravirine—Renal failure—Doxorubicin—urinary bladder cancer	0.000317	0.00115	CcSEcCtD
Etravirine—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000317	0.00334	CbGpPWpGaD
Etravirine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000317	0.00115	CcSEcCtD
Etravirine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000317	0.00115	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000315	0.00332	CbGpPWpGaD
Etravirine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000315	0.00114	CcSEcCtD
Etravirine—Abdominal pain—Etoposide—urinary bladder cancer	0.000314	0.00114	CcSEcCtD
Etravirine—Body temperature increased—Etoposide—urinary bladder cancer	0.000314	0.00114	CcSEcCtD
Etravirine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000314	0.00114	CcSEcCtD
Etravirine—Hepatitis—Epirubicin—urinary bladder cancer	0.000313	0.00114	CcSEcCtD
Etravirine—Eye disorder—Methotrexate—urinary bladder cancer	0.000313	0.00113	CcSEcCtD
Etravirine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000313	0.00113	CcSEcCtD
Etravirine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000312	0.00113	CcSEcCtD
Etravirine—Asthenia—Cisplatin—urinary bladder cancer	0.000311	0.00113	CcSEcCtD
Etravirine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000311	0.00113	CcSEcCtD
Etravirine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000309	0.00112	CcSEcCtD
Etravirine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000308	0.00112	CcSEcCtD
Etravirine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000307	0.00111	CcSEcCtD
Etravirine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000305	0.00111	CcSEcCtD
Etravirine—Angiopathy—Methotrexate—urinary bladder cancer	0.000304	0.0011	CcSEcCtD
Etravirine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000302	0.0011	CcSEcCtD
Etravirine—Dizziness—Fluorouracil—urinary bladder cancer	0.000302	0.0011	CcSEcCtD
Etravirine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000302	0.00109	CcSEcCtD
Etravirine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000297	0.00108	CcSEcCtD
Etravirine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000296	0.00107	CcSEcCtD
Etravirine—Vomiting—Gemcitabine—urinary bladder cancer	0.000296	0.00107	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000295	0.0031	CbGpPWpGaD
Etravirine—Mental disorder—Methotrexate—urinary bladder cancer	0.000293	0.00106	CcSEcCtD
Etravirine—Rash—Gemcitabine—urinary bladder cancer	0.000293	0.00106	CcSEcCtD
Etravirine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000293	0.00106	CcSEcCtD
Etravirine—Eye disorder—Epirubicin—urinary bladder cancer	0.000293	0.00106	CcSEcCtD
Etravirine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000293	0.00106	CcSEcCtD
Etravirine—Malnutrition—Methotrexate—urinary bladder cancer	0.000291	0.00106	CcSEcCtD
Etravirine—Headache—Gemcitabine—urinary bladder cancer	0.000291	0.00106	CcSEcCtD
Etravirine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000291	0.00105	CcSEcCtD
Etravirine—Vomiting—Fluorouracil—urinary bladder cancer	0.000291	0.00105	CcSEcCtD
Etravirine—Hepatitis—Doxorubicin—urinary bladder cancer	0.00029	0.00105	CcSEcCtD
Etravirine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000289	0.00304	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000289	0.00304	CbGpPWpGaD
Etravirine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000288	0.00105	CcSEcCtD
Etravirine—Rash—Fluorouracil—urinary bladder cancer	0.000288	0.00105	CcSEcCtD
Etravirine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000288	0.00104	CcSEcCtD
Etravirine—Headache—Fluorouracil—urinary bladder cancer	0.000286	0.00104	CcSEcCtD
Etravirine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000286	0.00104	CcSEcCtD
Etravirine—Asthenia—Etoposide—urinary bladder cancer	0.000285	0.00103	CcSEcCtD
Etravirine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000285	0.00103	CcSEcCtD
Etravirine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000285	0.003	CbGpPWpGaD
Etravirine—Angiopathy—Epirubicin—urinary bladder cancer	0.000284	0.00103	CcSEcCtD
Etravirine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000284	0.00103	CcSEcCtD
Etravirine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000283	0.00103	CcSEcCtD
Etravirine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000282	0.00102	CcSEcCtD
Etravirine—ABCB4—Metabolism—RRM2—urinary bladder cancer	0.000279	0.00294	CbGpPWpGaD
Etravirine—Nausea—Gemcitabine—urinary bladder cancer	0.000276	0.001	CcSEcCtD
Etravirine—Vomiting—Cisplatin—urinary bladder cancer	0.000276	0.000999	CcSEcCtD
Etravirine—Vision blurred—Methotrexate—urinary bladder cancer	0.000275	0.000996	CcSEcCtD
Etravirine—Mental disorder—Epirubicin—urinary bladder cancer	0.000275	0.000995	CcSEcCtD
Etravirine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000274	0.000994	CcSEcCtD
Etravirine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000274	0.00288	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000274	0.00288	CbGpPWpGaD
Etravirine—Rash—Cisplatin—urinary bladder cancer	0.000273	0.000991	CcSEcCtD
Etravirine—Dermatitis—Cisplatin—urinary bladder cancer	0.000273	0.00099	CcSEcCtD
Etravirine—Malnutrition—Epirubicin—urinary bladder cancer	0.000273	0.000989	CcSEcCtD
Etravirine—Diarrhoea—Etoposide—urinary bladder cancer	0.000272	0.000985	CcSEcCtD
Etravirine—Nausea—Fluorouracil—urinary bladder cancer	0.000272	0.000985	CcSEcCtD
Etravirine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000271	0.000982	CcSEcCtD
Etravirine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00027	0.000981	CcSEcCtD
Etravirine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00027	0.00284	CbGpPWpGaD
Etravirine—Anaemia—Methotrexate—urinary bladder cancer	0.000269	0.000977	CcSEcCtD
Etravirine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000269	0.000976	CcSEcCtD
Etravirine—Flatulence—Epirubicin—urinary bladder cancer	0.000269	0.000975	CcSEcCtD
Etravirine—Tension—Epirubicin—urinary bladder cancer	0.000268	0.000971	CcSEcCtD
Etravirine—Nervousness—Epirubicin—urinary bladder cancer	0.000265	0.000961	CcSEcCtD
Etravirine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000263	0.000954	CcSEcCtD
Etravirine—Malaise—Methotrexate—urinary bladder cancer	0.000263	0.000953	CcSEcCtD
Etravirine—Dizziness—Etoposide—urinary bladder cancer	0.000263	0.000952	CcSEcCtD
Etravirine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000262	0.00095	CcSEcCtD
Etravirine—Vertigo—Methotrexate—urinary bladder cancer	0.000262	0.00095	CcSEcCtD
Etravirine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000261	0.000947	CcSEcCtD
Etravirine—ABCB4—Metabolism—HPGDS—urinary bladder cancer	0.000259	0.00272	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—ENO2—urinary bladder cancer	0.000259	0.00272	CbGpPWpGaD
Etravirine—Nausea—Cisplatin—urinary bladder cancer	0.000258	0.000934	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000257	0.00271	CbGpPWpGaD
Etravirine—Vision blurred—Epirubicin—urinary bladder cancer	0.000257	0.000932	CcSEcCtD
Etravirine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000254	0.000921	CcSEcCtD
Etravirine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000253	0.000918	CcSEcCtD
Etravirine—Convulsion—Methotrexate—urinary bladder cancer	0.000253	0.000916	CcSEcCtD
Etravirine—Vomiting—Etoposide—urinary bladder cancer	0.000253	0.000916	CcSEcCtD
Etravirine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000252	0.000915	CcSEcCtD
Etravirine—Anaemia—Epirubicin—urinary bladder cancer	0.000252	0.000914	CcSEcCtD
Etravirine—ABCB4—Metabolism—GSTT1—urinary bladder cancer	0.000251	0.00264	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00025	0.00264	CbGpPWpGaD
Etravirine—Rash—Etoposide—urinary bladder cancer	0.00025	0.000908	CcSEcCtD
Etravirine—Dermatitis—Etoposide—urinary bladder cancer	0.00025	0.000907	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.00025	0.00263	CbGpPWpGaD
Etravirine—Headache—Etoposide—urinary bladder cancer	0.000249	0.000902	CcSEcCtD
Etravirine—Flatulence—Doxorubicin—urinary bladder cancer	0.000249	0.000902	CcSEcCtD
Etravirine—Tension—Doxorubicin—urinary bladder cancer	0.000248	0.000898	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000247	0.0026	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000247	0.0026	CbGpPWpGaD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000246	0.000894	CcSEcCtD
Etravirine—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000246	0.00259	CbGpPWpGaD
Etravirine—Malaise—Epirubicin—urinary bladder cancer	0.000246	0.000892	CcSEcCtD
Etravirine—Discomfort—Methotrexate—urinary bladder cancer	0.000245	0.000889	CcSEcCtD
Etravirine—Nervousness—Doxorubicin—urinary bladder cancer	0.000245	0.000889	CcSEcCtD
Etravirine—Vertigo—Epirubicin—urinary bladder cancer	0.000245	0.000889	CcSEcCtD
Etravirine—Syncope—Epirubicin—urinary bladder cancer	0.000245	0.000887	CcSEcCtD
Etravirine—Confusional state—Methotrexate—urinary bladder cancer	0.00024	0.00087	CcSEcCtD
Etravirine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00024	0.000869	CcSEcCtD
Etravirine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000238	0.000862	CcSEcCtD
Etravirine—Convulsion—Epirubicin—urinary bladder cancer	0.000236	0.000857	CcSEcCtD
Etravirine—Infection—Methotrexate—urinary bladder cancer	0.000236	0.000857	CcSEcCtD
Etravirine—Nausea—Etoposide—urinary bladder cancer	0.000236	0.000855	CcSEcCtD
Etravirine—Hypertension—Epirubicin—urinary bladder cancer	0.000236	0.000854	CcSEcCtD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000235	0.00247	CbGpPWpGaD
Etravirine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000234	0.000849	CcSEcCtD
Etravirine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000233	0.000846	CcSEcCtD
Etravirine—Anaemia—Doxorubicin—urinary bladder cancer	0.000233	0.000846	CcSEcCtD
Etravirine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000233	0.000845	CcSEcCtD
Etravirine—Anxiety—Epirubicin—urinary bladder cancer	0.000231	0.000839	CcSEcCtD
Etravirine—Skin disorder—Methotrexate—urinary bladder cancer	0.000231	0.000838	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000231	0.000836	CcSEcCtD
Etravirine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00023	0.000834	CcSEcCtD
Etravirine—Discomfort—Epirubicin—urinary bladder cancer	0.000229	0.000832	CcSEcCtD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000228	0.0024	CbGpPWpGaD
Etravirine—Malaise—Doxorubicin—urinary bladder cancer	0.000228	0.000825	CcSEcCtD
Etravirine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000228	0.0024	CbGpPWpGaD
Etravirine—Dry mouth—Epirubicin—urinary bladder cancer	0.000227	0.000823	CcSEcCtD
Etravirine—Vertigo—Doxorubicin—urinary bladder cancer	0.000227	0.000822	CcSEcCtD
Etravirine—Anorexia—Methotrexate—urinary bladder cancer	0.000227	0.000822	CcSEcCtD
Etravirine—Syncope—Doxorubicin—urinary bladder cancer	0.000226	0.000821	CcSEcCtD
Etravirine—ABCB1—lymph node—urinary bladder cancer	0.000226	0.00962	CbGeAlD
Etravirine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000226	0.00237	CbGpPWpGaD
Etravirine—Confusional state—Epirubicin—urinary bladder cancer	0.000224	0.000814	CcSEcCtD
Etravirine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000224	0.00236	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000222	0.00234	CbGpPWpGaD
Etravirine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000222	0.000804	CcSEcCtD
Etravirine—Infection—Epirubicin—urinary bladder cancer	0.000221	0.000802	CcSEcCtD
Etravirine—Shock—Epirubicin—urinary bladder cancer	0.000219	0.000794	CcSEcCtD
Etravirine—Convulsion—Doxorubicin—urinary bladder cancer	0.000219	0.000793	CcSEcCtD
Etravirine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000218	0.000792	CcSEcCtD
Etravirine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000218	0.00079	CcSEcCtD
Etravirine—Hypertension—Doxorubicin—urinary bladder cancer	0.000218	0.00079	CcSEcCtD
Etravirine—Skin disorder—Epirubicin—urinary bladder cancer	0.000216	0.000784	CcSEcCtD
Etravirine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000215	0.00078	CcSEcCtD
Etravirine—Insomnia—Methotrexate—urinary bladder cancer	0.000215	0.00078	CcSEcCtD
Etravirine—Anxiety—Doxorubicin—urinary bladder cancer	0.000214	0.000776	CcSEcCtD
Etravirine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000214	0.000775	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000213	0.000774	CcSEcCtD
Etravirine—Discomfort—Doxorubicin—urinary bladder cancer	0.000212	0.00077	CcSEcCtD
Etravirine—Anorexia—Epirubicin—urinary bladder cancer	0.000212	0.000769	CcSEcCtD
Etravirine—Somnolence—Methotrexate—urinary bladder cancer	0.000211	0.000767	CcSEcCtD
Etravirine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00021	0.000762	CcSEcCtD
Etravirine—ABCB4—Metabolism—NQO1—urinary bladder cancer	0.000209	0.0022	CbGpPWpGaD
Etravirine—Confusional state—Doxorubicin—urinary bladder cancer	0.000208	0.000753	CcSEcCtD
Etravirine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000207	0.00075	CcSEcCtD
Etravirine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000205	0.000745	CcSEcCtD
Etravirine—Fatigue—Methotrexate—urinary bladder cancer	0.000205	0.000744	CcSEcCtD
Etravirine—Infection—Doxorubicin—urinary bladder cancer	0.000205	0.000742	CcSEcCtD
Etravirine—Pain—Methotrexate—urinary bladder cancer	0.000203	0.000738	CcSEcCtD
Etravirine—Shock—Doxorubicin—urinary bladder cancer	0.000203	0.000735	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000202	0.00213	CbGpPWpGaD
Etravirine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000202	0.000732	CcSEcCtD
Etravirine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000202	0.000731	CcSEcCtD
Etravirine—Insomnia—Epirubicin—urinary bladder cancer	0.000201	0.00073	CcSEcCtD
Etravirine—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000201	0.00212	CbGpPWpGaD
Etravirine—Skin disorder—Doxorubicin—urinary bladder cancer	0.0002	0.000725	CcSEcCtD
Etravirine—Paraesthesia—Epirubicin—urinary bladder cancer	0.0002	0.000725	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000199	0.0021	CbGpPWpGaD
Etravirine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000199	0.000722	CcSEcCtD
Etravirine—Somnolence—Epirubicin—urinary bladder cancer	0.000198	0.000718	CcSEcCtD
Etravirine—Anorexia—Doxorubicin—urinary bladder cancer	0.000196	0.000712	CcSEcCtD
Etravirine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000196	0.000711	CcSEcCtD
Etravirine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000195	0.000705	CcSEcCtD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000194	0.00205	CbGpPWpGaD
Etravirine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000194	0.000702	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000193	0.00204	CbGpPWpGaD
Etravirine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000192	0.000697	CcSEcCtD
Etravirine—Fatigue—Epirubicin—urinary bladder cancer	0.000192	0.000696	CcSEcCtD
Etravirine—Constipation—Epirubicin—urinary bladder cancer	0.00019	0.00069	CcSEcCtD
Etravirine—Pain—Epirubicin—urinary bladder cancer	0.00019	0.00069	CcSEcCtD
Etravirine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000188	0.000682	CcSEcCtD
Etravirine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000188	0.000682	CcSEcCtD
Etravirine—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000187	0.00197	CbGpPWpGaD
Etravirine—Insomnia—Doxorubicin—urinary bladder cancer	0.000186	0.000676	CcSEcCtD
Etravirine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000185	0.000671	CcSEcCtD
Etravirine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000183	0.000665	CcSEcCtD
Etravirine—Somnolence—Doxorubicin—urinary bladder cancer	0.000183	0.000664	CcSEcCtD
Etravirine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000182	0.00066	CcSEcCtD
Etravirine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000182	0.00192	CbGpPWpGaD
Etravirine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000179	0.000649	CcSEcCtD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000179	0.00189	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000178	0.00188	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000178	0.00187	CbGpPWpGaD
Etravirine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000645	CcSEcCtD
Etravirine—Fatigue—Doxorubicin—urinary bladder cancer	0.000178	0.000644	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000176	0.00186	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000176	0.00186	CbGpPWpGaD
Etravirine—Constipation—Doxorubicin—urinary bladder cancer	0.000176	0.000639	CcSEcCtD
Etravirine—Pain—Doxorubicin—urinary bladder cancer	0.000176	0.000639	CcSEcCtD
Etravirine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000176	0.000638	CcSEcCtD
Etravirine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000176	0.000638	CcSEcCtD
Etravirine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000175	0.000635	CcSEcCtD
Etravirine—ABCB4—Metabolism—GSTP1—urinary bladder cancer	0.000174	0.00183	CbGpPWpGaD
Etravirine—Asthenia—Methotrexate—urinary bladder cancer	0.000171	0.000619	CcSEcCtD
Etravirine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.00017	0.00179	CbGpPWpGaD
Etravirine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00017	0.000615	CcSEcCtD
Etravirine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000168	0.000611	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000168	0.00177	CbGpPWpGaD
Etravirine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000164	0.000595	CcSEcCtD
Etravirine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000163	0.00059	CcSEcCtD
Etravirine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000163	0.00059	CcSEcCtD
Etravirine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000163	0.00059	CcSEcCtD
Etravirine—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000162	0.00171	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—TYMS—urinary bladder cancer	0.000162	0.0017	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GSTM1—urinary bladder cancer	0.00016	0.00168	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—NCOR1—urinary bladder cancer	0.00016	0.00168	CbGpPWpGaD
Etravirine—Asthenia—Epirubicin—urinary bladder cancer	0.00016	0.000579	CcSEcCtD
Etravirine—Dizziness—Methotrexate—urinary bladder cancer	0.000157	0.00057	CcSEcCtD
Etravirine—ABCB4—Metabolism—GPX1—urinary bladder cancer	0.000153	0.00161	CbGpPWpGaD
Etravirine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000152	0.000552	CcSEcCtD
Etravirine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000152	0.00055	CcSEcCtD
Etravirine—Vomiting—Methotrexate—urinary bladder cancer	0.000151	0.000548	CcSEcCtD
Etravirine—ABCB4—Metabolism—ERCC2—urinary bladder cancer	0.00015	0.00158	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.00015	0.00158	CbGpPWpGaD
Etravirine—Rash—Methotrexate—urinary bladder cancer	0.00015	0.000544	CcSEcCtD
Etravirine—Dermatitis—Methotrexate—urinary bladder cancer	0.00015	0.000543	CcSEcCtD
Etravirine—Headache—Methotrexate—urinary bladder cancer	0.000149	0.00054	CcSEcCtD
Etravirine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000148	0.00156	CbGpPWpGaD
Etravirine—Asthenia—Doxorubicin—urinary bladder cancer	0.000148	0.000536	CcSEcCtD
Etravirine—Dizziness—Epirubicin—urinary bladder cancer	0.000147	0.000534	CcSEcCtD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000144	0.00152	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000143	0.00151	CbGpPWpGaD
Etravirine—Vomiting—Epirubicin—urinary bladder cancer	0.000142	0.000513	CcSEcCtD
Etravirine—Nausea—Methotrexate—urinary bladder cancer	0.000141	0.000512	CcSEcCtD
Etravirine—ABCB4—Metabolism—MTHFR—urinary bladder cancer	0.000141	0.00149	CbGpPWpGaD
Etravirine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000141	0.000511	CcSEcCtD
Etravirine—Rash—Epirubicin—urinary bladder cancer	0.00014	0.000509	CcSEcCtD
Etravirine—Dermatitis—Epirubicin—urinary bladder cancer	0.00014	0.000508	CcSEcCtD
Etravirine—Headache—Epirubicin—urinary bladder cancer	0.000139	0.000506	CcSEcCtD
Etravirine—Dizziness—Doxorubicin—urinary bladder cancer	0.000136	0.000494	CcSEcCtD
Etravirine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000134	0.00141	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000134	0.00141	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000132	0.00139	CbGpPWpGaD
Etravirine—Nausea—Epirubicin—urinary bladder cancer	0.000132	0.000479	CcSEcCtD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000131	0.00138	CbGpPWpGaD
Etravirine—Vomiting—Doxorubicin—urinary bladder cancer	0.000131	0.000475	CcSEcCtD
Etravirine—Rash—Doxorubicin—urinary bladder cancer	0.00013	0.000471	CcSEcCtD
Etravirine—Dermatitis—Doxorubicin—urinary bladder cancer	0.00013	0.00047	CcSEcCtD
Etravirine—Headache—Doxorubicin—urinary bladder cancer	0.000129	0.000468	CcSEcCtD
Etravirine—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000123	0.0013	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000123	0.00129	CbGpPWpGaD
Etravirine—Nausea—Doxorubicin—urinary bladder cancer	0.000122	0.000444	CcSEcCtD
Etravirine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000122	0.00129	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000122	0.00128	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000121	0.00128	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000121	0.00127	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00012	0.00126	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000117	0.00124	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	0.000117	0.00123	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000116	0.00123	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PPARG—urinary bladder cancer	0.000115	0.00121	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000114	0.0012	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000112	0.00118	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000112	0.00118	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000111	0.00117	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CREBBP—urinary bladder cancer	0.00011	0.00116	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	9.92e-05	0.00104	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.57e-05	0.00101	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PTGS2—urinary bladder cancer	9.01e-05	0.000949	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	8.76e-05	0.000923	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.73e-05	0.000919	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.69e-05	0.000915	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	8.53e-05	0.000898	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	8.22e-05	0.000865	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.06e-05	0.000849	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	8.02e-05	0.000844	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.95e-05	0.000837	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PTEN—urinary bladder cancer	7.86e-05	0.000828	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	7.79e-05	0.00082	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NAT1—urinary bladder cancer	7.79e-05	0.00082	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.66e-05	0.000807	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.62e-05	0.000802	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	7.6e-05	0.0008	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NAT1—urinary bladder cancer	7.6e-05	0.0008	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.52e-05	0.000792	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—EP300—urinary bladder cancer	7.5e-05	0.000789	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	7.49e-05	0.000789	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.41e-05	0.00078	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.31e-05	0.00077	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	7.12e-05	0.00075	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	7.1e-05	0.000748	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	7.1e-05	0.000748	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.98e-05	0.000735	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	6.95e-05	0.000732	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	6.49e-05	0.000684	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.46e-05	0.00068	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.41e-05	0.000675	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.38e-05	0.000672	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	6.26e-05	0.000659	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.24e-05	0.000657	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	6.06e-05	0.000638	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	5.91e-05	0.000622	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.9e-05	0.000621	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	5.85e-05	0.000616	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	5.76e-05	0.000607	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.63e-05	0.000593	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	5.52e-05	0.000581	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.45e-05	0.000574	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.44e-05	0.000573	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.38e-05	0.000567	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.19e-05	0.000546	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.04e-05	0.000531	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.94e-05	0.00052	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.73e-05	0.000498	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.72e-05	0.000497	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.68e-05	0.000493	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.68e-05	0.000493	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.61e-05	0.000485	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.53e-05	0.000477	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.52e-05	0.000476	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.42e-05	0.000465	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.31e-05	0.000454	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.3e-05	0.000453	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.28e-05	0.000451	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.27e-05	0.000449	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.21e-05	0.000443	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.18e-05	0.00044	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NAT2—urinary bladder cancer	4.16e-05	0.000439	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.13e-05	0.000435	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.89e-05	0.00041	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.86e-05	0.000406	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.71e-05	0.000391	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.68e-05	0.000388	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.64e-05	0.000383	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.6e-05	0.000379	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.55e-05	0.000374	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.41e-05	0.000359	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.41e-05	0.000359	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.39e-05	0.000357	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.36e-05	0.000354	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.33e-05	0.000351	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.33e-05	0.000351	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.31e-05	0.000348	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.26e-05	0.000343	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.23e-05	0.00034	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.11e-05	0.000328	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.11e-05	0.000328	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.09e-05	0.000326	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.02e-05	0.000318	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.02e-05	0.000318	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.97e-05	0.000313	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.84e-05	0.000299	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.75e-05	0.00029	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.68e-05	0.000283	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.67e-05	0.000281	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.57e-05	0.00027	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.51e-05	0.000264	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.43e-05	0.000256	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.33e-05	0.000245	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.29e-05	0.000241	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.24e-05	0.000236	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.22e-05	0.000234	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.22e-05	0.000233	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.13e-05	0.000224	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.12e-05	0.000223	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.11e-05	0.000222	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.11e-05	0.000222	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.09e-05	0.00022	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.08e-05	0.000219	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.06e-05	0.000217	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.06e-05	0.000217	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000216	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000216	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.02e-05	0.000213	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.02e-05	0.000213	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.00021	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.98e-05	0.000209	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.97e-05	0.000207	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.94e-05	0.000205	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.93e-05	0.000204	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.92e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.92e-05	0.000202	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.86e-05	0.000196	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.84e-05	0.000194	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.82e-05	0.000191	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.81e-05	0.00019	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.7e-05	0.000179	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000174	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.51e-05	0.000159	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.47e-05	0.000155	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.45e-05	0.000153	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.42e-05	0.000149	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000145	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000145	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	0.000139	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000135	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000133	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000128	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000125	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.19e-05	0.000125	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.16e-05	0.000122	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	0.000118	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	0.000114	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.04e-05	0.000109	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.01e-05	0.000106	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—EP300—urinary bladder cancer	9.88e-06	0.000104	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—EP300—urinary bladder cancer	9.64e-06	0.000102	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.45e-06	9.95e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.08e-06	9.56e-05	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.01e-06	9.49e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.73e-06	9.19e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.14e-06	7.52e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.23e-06	6.56e-05	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.94e-06	6.26e-05	CbGpPWpGaD
